Comparing two EoE treatments on esophagus widening
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with EoE and have active inflammation (high eosinophil count in a biopsy)
- You weigh at least 40 kg (about 88 pounds)
- You are willing to keep the same diet during the study
- You are willing to receive weekly injections
- You have not already failed treatment with Dupixent or swallowed budesonide
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
Hear when a new Eosinophilic Esophagitis (EoE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.